← Back to Clinical Trials
Recruiting NCT07448896

NCT07448896 Alterations in Mast Cell and Macrophage Infiltration, as Well as Micro Vessel Density

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07448896
Status Recruiting
Phase
Sponsor General Committee of Teaching Hospitals and Institutes, Egypt
Condition Obesity
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2026-04-15
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
bariatric surgery laparoscopic sleeve gastrectomylean control patients undergoing endoscopic biopsy for benign or malignant gastric conditions.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2026-04-15 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Obesity is a global health problem that has reached epidemic proportions, affecting more than one billion people worldwide and significantly increasing the risk of multiple comorbidities, including type 2 diabetes, cardiovascular diseases, and cancer (World Health Organization, 2024). Increasing evidence suggests that chronic low-grade inflammation associated with obesity plays a critical role in the development of obesity-related malignancies, including gastric cancer. Adipose tissue dysfunction in obesity leads to the recruitment and activation of various immune cells, such as macrophages and mast cells, which contribute to a pro-inflammatory microenvironment through the release of cytokines, growth factors, and angiogenic mediators.

Eligibility Criteria

Inclusion Criteria: * Adult patients undergoing bariatric surgery (laparoscopic sleeve gastrectomy). * BMI \> 35 kg/m² * All participants underwent preoperative evaluation, including blood tests and assessment by a multidisciplinary team (nutritionist, psychiatrist, endocrinologist, radiologist, anesthesiologist, and surgeon). Exclusion Criteria: * Patients with secondary causes of obesity, such as Cushing's syndrome or polycystic ovary syndrome (PCOS). * Patients with malignant gastric conditions or previous gastric surgery. * Patients with systemic inflammatory diseases, autoimmune disorders, or chronic infections that may influence immune cell infiltration. * Patients with incomplete clinical data or poor-quality tissue samples. * Patients taking anti-inflammatory, immunosuppressive, or corticosteroid therapy within the last 3 months before sampling.

Contact & Investigator

Central Contact

Mohamed H Ashour, PhD

✉ dr.mhany@gmail.com

📞 00201002600970

Frequently Asked Questions

Who can join the NCT07448896 clinical trial?

This trial is open to participants of all sexes, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07448896 currently recruiting?

Yes, NCT07448896 is actively recruiting participants. Contact the research team at dr.mhany@gmail.com for enrollment information.

Where is the NCT07448896 trial being conducted?

This trial is being conducted at Alexandria, Egypt.

Who is sponsoring the NCT07448896 clinical trial?

NCT07448896 is sponsored by General Committee of Teaching Hospitals and Institutes, Egypt. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology